ZINZINO AB (PUBL): PRELIMINARY SALES REPORT JANUARY 2019

STRONG SALES GROWTH DURING JANUARY; REVENUE INCREASED 14% COMPARED WITH THE PREVIOUS YEAR.

Growth in all regions resulted in revenues for Zinzino's sales markets increasing by 24% to SEK 49.9 (40.1) million. Higher share of internal production during the month meant that Faun Pharma's external sales decreased by 50% and amounted to SEK 3.3 (6.6) million. Overall, the Group increased revenues by 14% to SEK 53.2 (46.7) million compared with the previous year.

Revenues distributed as follows:

Regions, SEK million Jan-19 Jan-18 Change
Nordic Countries 33,3 35,9 -7%
Baltic States 4,3 3,7 17%
Central Europe 12,9 5,0 157%
South Europe 1,0 0,4 130%
North America 1,7 1,7 5%
53,2 46,7 14%

 
For more information please contact:
Dag Bergheim Pettersen, CEO Zinzino, tel.
+47 (0) 932 25 700 www.zinzino.se

Pictures for free publication:
Marcus Tollbom, tel. +46 (0) 70-190 03 12

Certified Adviser:
Erik Penser Bank Aktiebolag
: +46 (0)8 463 83 00 Email: certifiedadviser@penser.se 

Tags:

About Us

Zinzino AB (publ.) is a global Direct Sales company that markets and sells test-based nutrition, skincare and life-style products. Zinzino owns the Norwegian company BioActive Foods AS and the research and production unit Faun Pharma AS. Zinzino is based in Gothenburg, with additional offices in Helsinki, Riga, Oslo, Florida and Adelaide. Zinzino is a public company and its shares are listed on Nasdaq First North.

Subscribe

Documents & Links